Диссертация (Клинико-фармакологические подходы к персонализации назначения препаратов метаболического ряда при лечении пациентов с ишемической болезнью сердца), страница 51

– V.161. – P. 271-277.308.Levy, S. Group of South France Investigators. Combination treatmentwith trimetazidine and diltiazem in patients with coronary artery disease [Text] /S.Levy // Am. J. Cardiol. – 1995. – V.76. – P.12B-16B.309. MacDonald, J.I.S. Phospholipid fatty acid remodeling in mammaliancells [Text] /J.I.S. MacDonald, H. Sprecher // Biochim.

Biophys. Acta. – 1991. –V.1084. – P.105-119.310.Mallal, S. HLA-B*5701 screening for hypersensitivity to abacavir[Text] / S. Mallal, E. Phillips, G. Carosi et al.// N. Engl. J. Med. – 2008. – V.358. –P.568-579.311. Maridonneau-Parini, I. Effects of trimetazidine on membrane damageinduced by oxygen free radicals in human cells [Text] /I. Maridonneau-Parini, C.Harpey //Br.

J. Clin. Pharmacol. – 1985. – V.20. – P.148-151.312.Marin-Garcia, J. Mitochondria and the heart [Text] / J. Marin-Garcia. –New Jersey: Springer, 2005. – 415p.313. Mathijssen, R.H. Prediction of irinotecan pharmacokinetics by use ofcytochrome P450 3A4 phenotyping probes [Text] / R.H. Mathijssen, F.A. de Jong,R.H. van Schaik et al. // J. Natl. Cancer Inst. – 2004. – V.96, №21. – P.1585-1592.314. Mega, J.L. Cytochrome P450 genetic polymorphisms and the response toprasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[Text] / J.L. Mega, S.L.

Close, S.D. Wiviott et al. // Circulation. – 2009. – V.119. –P.2553-2560.341315.Mega, J.L. Cytochrome p-450 polymorphisms and response toclopidogrel [Text]/ J.L. Mega, S.L. Close, S.D. Wiviott et al. // N. Engl. J. Med. –2009. – V.360. – P.354-362.316.Miettinen, O.

Efficacy of therapeutic practice: will epidemiologyprovide the answers? [Text] / O. Miettinen // Drug therapeutics / ed. by K. Melmon. –Edinburgh, 1980. – P. 201-208.317. Minsky, M. Memoir on inventing the confocal scanning microscopy[Text] / M. Minsky // Scanning. – 1988. – V.10 – P.

128 – 138.318. Minsky, M. Microscopy apparatus [Text] / M. Minsky. - US Pat, 1961. –467 p.319.Moricke, A. Longterm results of five consecutive trials in childhoodacute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to2000 [Text] / A. Moricke, M. Zimmermann, A. Reiter // Leukemia. – V.24. – P.265284.320. Morin, D. Inhibition of mitochondrial membrane permeability as aputative pharmacological target for cardioprotection [Text] / D. Morin, R.

Assaly, S.Paradis, A. Berdeaux //Curr. Med. Chem. - 2009. – Vol.16(33). – P. 4382-4398.321. Napoli,P.Di.Longtermcardioprotectiveactionoftrimetazidine and potential effect on the inflammatory process in patientswith ischemic dilated cardiomyopathy [Text] / P. Di. Napoli, A.A. Taccardi,A. Barsotti // Heart. – 2005. – V.91. – P.161-165.322.Nemeroff, C.B., Musselman D.L. Are platelets the link betweendepression and ischemic heart disease? [Text] /C.B. Nemeroff, D.L. Musselman//Am. Heart J.

– 2000. – V.140. - P.S57-62.323.Passeron, J. Effectiveness of trimetazidine in stable effort angina due tochronic coronary insufficiency: a double-blind versus placebo study [Text] /J.Passeron // Press. Med. – 1986. – V.15. – P.1775-1778.342324. Pawley, J.B. Handbook of biological confocal microscopy [Text] / J.B.Pawley. - New York: Plenum Press. – 1995. – 632p.325. Perez-Castrillon, J.L.

Vitamin D levels and lipid response to atorvastatin[Text] / J.L. Perez-Castrillon, L. Abad Manteca, G. Vega et al.// Int. J. Endocrinol. –2010. – V.20,№10. – P.320-321.326. Personalized medication card [Text] : pat. US 2005/0110268 A1 : Int.Cl.7 G09C 3/00 ; US.

Cl. 283/75 / O. M. Schone, Charlotte NC. – № 10/718,895 ;appl. 21.11.2003 ; publ. 26.05.2005. – 2 p.327.Personalized medicine service [Text] : pat. US 2005/0246314 A1 : Int.Cl.7 G06F 7/00 ; US. Cl. 707/1 / J. S. Eder, Mill Creek WA. – № 11/094,171 ; appl.31.03.2005 ; publ. 03.11.2005. – 43 p.328.Pirmohamed, M. Genetic factors in the predisposition to drug-inducedhypersensitivity reactions [Text] /M. Pirmohamed // AAPS J. – 2006. – V.8. – P.E20E26.329. Pogosova, G.V.

Incidence of anxiety, depressive symptoms and theirrelationship with cardiovascular risk factors in men aged 35-64 [Text] /G.V.Pogosova, D.V. Nebieridze, L.D. Ozdoeva et al. // Eur. J. Cardiovasc. Prev. Rehabil.– 2004. – V.11 (suppl.1) – P.17.330.Poroikov, V. PASS: Identification of probable targets and mechanismsof toxicity [Text] / V. Poroikov, D. Filimonov, A. Lagunin et al.// SAR&QSAR inEnviron Res. – 2007. – V.18. – №1-2.

– P.101-110.331.Psychosocial variables are associated with atherosclerosis risk factorsamong woman with chest pain: The WISE study [Text]// Psychosom. Med. – 2001. –V.63. – P.282-288.332. Pupure, J. Neuroprotective properties of mildronate, a mitochondriatargeted small molecule [Text] / J. Pupure, S. Isajevs, E. Scapare et al.

// Neurosci.Lett. - 2010. - Vol. 470(2). – P.100-105.343333.Rajadhyaksha, M. In vivo confocal scanning laser microscopy of humanskin: melanin provides strong contrast [Text] / M. Rajadhyaksha, M. Grossman, D.Esterowitz et al. // J. Invest. Dermatol. – 1995. – V.104. – P. 946—952.334.

Rebecchi, I.M. ABCB1 and ABCC1 expression in peripheralmononuclear cells is influenced by gene polymorphisms and atorvastatin treatment[Text] / I.M. Rebecchi, A.C. Rodrigues, S.S. Arazi et al. // Biochem. Pharmacol. –2009. – V.77, №1. – P.66-75.335.Rosengren,A.INTERHEARTinvestigators.Associationofpsychosocial risk factors with risk of acute myocardial infarction in 11119 cases and13648 controls from 52 countries (the INTERHEART study): case-control study[Text] /A. Rosengren, S. Hawken, S. Ounpuu et al. // Lancet. – 2004. – V.364. –P.953-962.336. Roskopf, D.

Pharmacogenomics in routine medical care [Text] /D.Roskopf, H.E. Meyer zu Schwabedissen, H.K. Kroemer, W. Siegmund // Dtsch.Med. Wochenschr. – 2010. – V.135,№4. – P.133-144.337.Sackett, D.L. Evidence-Based Medicine: How to practice and teachEBM [Text] / D.L. Sackett, S.E. Straus, W.S. Richardson et al. – New York:Churchill Livingstone, 2000.

– 261p.338. Samani, N.J. Large scale association analysis of novel genetic loci forcoronary artery disease [Text] / N.J. Samani, P. Deloukas, J. Erdmann et al.//Arterioscler. Thromb. Vasc. Biol. – 2009. – V.29. – P.774-780.339.Schaeffeler,E.ComprehensiveanalysisofthiopurineS-methyltransferase phenotype-genotype correlation in a large population of GermanCaucasians and identification of novel TPMT variants [Text] / E. Schaeffeler, C.Fischer, D. Brockmeier et al. // Pharmacogenetics. – 2004. – Vol.14. – P.407-417.344340.Schofield, R.S.

Role of metabolically active drugs in the management ofischemic heart disease [Text] / R.S. Schofield, J.A. Hill // Am. J. Cardiovasc. Drugs.– 2001. – V.1. – P.23-35.341. Serretti, A. Common genetic, clinical, demographic and psychosocialpredictors of response to pharmacotherapy in mood and anxiety disorders [Text] / A.Serretti, A.

Chiesa, R. Calati et al. // Int. Clin. Psychopharmacol. – 2009. – V.24. –P.1-18.342.Severus, W.E. Omega-3 fatty acids, homocysteine, and the increasedrisk of cardiovascular mortality in major depressive disorder [Text] /W.E. Severus,A.B. Littman, A.L. Stoll // Harv. Rev. Psychiatr. – 2001. – V.9. – P.280-293.343. Sheppard, C.J.R. Effect of spherical aberration on the imaging propertiesof scanning optical microscopes [Text] /C.J.R.

Sheppard, T. Wilson //Applied Optics.– 1979. – V.18. – P. 1058.344.Sherwood, A. Impaired endothelial function in coronary heart diseasepatients with depressive symptomatology [Text] /A. Sherwood, A.L. Hinderliter, L.L.Watkins et al.// J. Am. Coll. Cardiol. – 2005. – V.46. – P.656-659.345. Sjoqvist, F. The convergence of conventional therapeutic drugmonitoring and pharmacogenetic testing in personalized medicine: focus onantidepressants [Text] / F. Sjoqvist, E.

Eliasson // Clin. Pharmacol. Ther. – V.81. –P.899-902.346.Skarda, I. Modulation of myocardial energy metabolism with mildronate– an effective approach in the treatment of chronic heart failure [Text] / I. Skarda, D.Klicare, V. Dzerve et al.// Proceedings of the Latvian academy of sciences. – 2001. –V.55, №2-3. – P.73-78.347. Stolley, P. The public health, the university, and pharmacoepidemiology[Text] / P. Stolley, J.-R.

Laporte // Pharmacoepidemiology / ed. by B. Strom. – 3rd ed.– New York, 2000. – P. 85-90.345348.Swynghedauw, B. Heart failure as a disease of adaptation [Text] / B.Swynghedauw, L. Rappaport, K. Schwartz // Cardiac hypertrophy and failure / ed. byB. Swynghedauw. – London ; Paris, 1990. – P. 679-686.349. System for developing assays for personalized medicine [Text] : pat.US20020048755 A1 ; Int. Cl.7 C12Q 1/68, G01N 33/48 ; US. Cl. 435/6, 435/7.21,435/960, 435/40.5, 435/40.52, 424/9.1, 424/9.2, 424/9.34, 514/44 / J. M.

Cohen,Potomac MD. – № US 09/769,298 ; appl. 26.01.2001 ; publ. 25.04.2002. – 5 p.350. Szwed, H. Trimpol II: combination treatment of stable effort anginausing trimetazidine and metoprolol: results ofa randomized, double blind,multicentre study [Text] / H. Szwed, Z. Sadowski, W. Elicowski et al. // Eur. Heart J.– 2001. – V.22, N2. – P.2267-2274.351.Takashi, E. Activation of mitochondrial KATP channel elicits latepreconditioning against myocardial infarction via protein kinase C signaling pathway[Text] /E.

Takashi, Y. Wang, M. Ashraf// Circ. Res. – 1999. – V.85. – P.1146-1153.352. Taegtmeyer, H. Energy substrate metabolism, myocardial ischemia, andtargets for pharmacotherapy [Text] / H. Taegtmeyer, L.M. King, B.E. Jones// Am. J.Cardiol. – 1998. – V.82. – P.54K-60K.353. The Task Force for the management of arterial hypertension of theEuropean Society of Hypertension and of the European Society of Cardiology. 2007Guidelines for the management of arterial hypertension [Text] // J.

Hypertens. – 2007.– V. 25. – P. 1105–1187.354. Waning, B. Pharmacoepidemiology: Principles and Practice [Text] / B.Waning, M. Montagne. - McGraw-Hill Companies, 2000. – 209p.355.Williams, F.M. Trimetazidine inhibits neutrophil accumulation aftermyocardial ischaemia and reperfusion in rabbits [Text] /F.M. Williams, K. Tanda, M.Kus, T.